Home / Health / FDA Weighs Peptide Use for Wellness Trends
FDA Weighs Peptide Use for Wellness Trends
15 Apr
Summary
- FDA panel to review popular peptides in July.
- Peptides are popular with wellness influencers online.
- Advisers will discuss peptides for various health conditions.
In July, the U.S. Food and Drug Administration will gather a panel of external advisers to scrutinize the production of popular peptides by compounding pharmacies. This review concerns over a dozen peptides, which are short amino acid chains vital for biological functions.
Previously, in 2023, the FDA restricted compounding pharmacies from manufacturing these peptides, citing potential safety concerns including immunogenicity, toxicity, and impurities. Regulators emphasized that many peptides lack sufficient human testing and could pose risks.
Despite these concerns, peptides have surged in popularity, widely promoted by wellness influencers for weight loss and recovery. This trend is partly fueled by the success of GLP-1 weight-loss drugs.
The advisory committee will convene on July 23 to discuss BPC-157, KPV, TB-500, and MOTS-c for various conditions. On July 24, the panel will evaluate emideltide, semax, and epitalon for issues like opioid withdrawal and insomnia.
